Increased expression of IRF4 was associated with an increased risk for the development of de novo AML and MDS (OR = 3.90; 95% CI, 2.36-6.44, Pmeta = 1.0 × 10–7), consistent with our SNP-level findings (Figure 3). Here, IRF4 is linked to acute myeloid leukemia.